192 related articles for article (PubMed ID: 12014649)
1. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
[TBL] [Abstract][Full Text] [Related]
2. Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody.
Matsumoto H; Liao S; Arakawa F; Ueno A; Abe H; Awasthi A; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(4):2001-7. PubMed ID: 12174877
[TBL] [Abstract][Full Text] [Related]
3. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
[TBL] [Abstract][Full Text] [Related]
4. SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis.
Sakurai N; Kudo T; Suzuki M; Tsumoto K; Takemura S; Kodama H; Ebara S; Teramae A; Katayose Y; Shinoda M; Kurokawa T; Hinoda Y; Imai K; Matsuno S; Kumagai I
Biochem Biophys Res Commun; 1999 Mar; 256(1):223-30. PubMed ID: 10066451
[TBL] [Abstract][Full Text] [Related]
5. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
[TBL] [Abstract][Full Text] [Related]
6. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
7. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M
Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model.
Yamamoto T; Arakawa F; Nakamura K; Senba T; Tomita Y; Ikeda S; Kuroki M
Cancer Immunol Immunother; 1999 Jul; 48(4):165-71. PubMed ID: 10431685
[TBL] [Abstract][Full Text] [Related]
9. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T
J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598
[TBL] [Abstract][Full Text] [Related]
10. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
[TBL] [Abstract][Full Text] [Related]
13. Construction and characterization of a novel superantigen fusion protein: bFGF/SEB.
Wang L; Zhang H; Zhang S; Yu M; Yang X
Cancer Invest; 2009 May; 27(4):376-83. PubMed ID: 19160106
[TBL] [Abstract][Full Text] [Related]
14. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
15. Immune response during tumor therapy with antibody-superantigen fusion proteins.
Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549
[TBL] [Abstract][Full Text] [Related]
16. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.
Riesbeck K; Billström A; Tordsson J; Brodin T; Kristensson K; Dohlsten M
Clin Diagn Lab Immunol; 1998 Sep; 5(5):675-82. PubMed ID: 9729535
[TBL] [Abstract][Full Text] [Related]
17. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
[TBL] [Abstract][Full Text] [Related]
19. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation.
Tiedemann RE; Fraser JD
J Immunol; 1996 Nov; 157(9):3958-66. PubMed ID: 8892628
[TBL] [Abstract][Full Text] [Related]
20. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN
Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
